Embecta (NASDAQ:EMBC) Insider Jeffrey Mann Purchases 20,000 Shares of Stock

Embecta Corp. (NASDAQ:EMBC) insider Jeffrey Mann bought 20,000 shares of the firm’s stock in a transaction on Wednesday, August 12th. The shares were purchased at an average price of $4.99 per share, for a total transaction of $99,800.00. Following the completion of the transaction, the insider owned 262,915 shares of the company’s stock, valued at $1,311,945.85. This represents a 8.23% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Embecta Trading Up 8.5%

Shares of EMBC stock traded up $0.41 during mid-day trading on Thursday, reaching $5.16. The stock had a trading volume of 659,113 shares, compared to its average volume of 1,586,592. The company has a market cap of $292.08 million, a P/E ratio of 3.48 and a beta of 0.81. Embecta Corp. has a 12-month low of $2.77 and a 12-month high of $15.55. The business has a 50-day simple moving average of $3.43 and a 200 day simple moving average of $6.46.

Embecta (NASDAQ:EMBC) last issued its quarterly earnings data on Friday, August 7th. The company reported $0.56 EPS for the quarter, beating analysts’ consensus estimates of $0.27 by $0.29. The firm had revenue of $271.70 million for the quarter, compared to analysts’ expectations of $254.53 million. Embecta had a net margin of 8.59% and a negative return on equity of 19.25%. The firm’s revenue was down 8.1% on a year-over-year basis. During the same period in the prior year, the company earned $1.12 EPS. Embecta has set its FY 2026 guidance at 1.800-1.900 EPS. Research analysts anticipate that Embecta Corp. will post 1.85 EPS for the current year.

Embecta Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 15th. Stockholders of record on Thursday, August 27th will be given a $0.01 dividend. The ex-dividend date is Thursday, August 27th. This represents a $0.04 annualized dividend and a dividend yield of 0.8%. Embecta’s dividend payout ratio is currently 2.70%.

More Embecta News

Here are the key news stories impacting Embecta this week:

• Negative Sentiment: The lawsuit, filed in federal court in New Jersey, alleges that Embecta and certain executives misrepresented the commercial stability of the company’s insulin pen-needle business. The allegations concern investors who purchased Embecta securities between November 25, 2025, and May 4, 2026, and have not been proven in court. EMBC Securities Lawsuit: Embecta Securities Fraud Class Action is Pending
• Negative Sentiment: A wave of investor-alert releases from SBS Law, Kaplan Fox, DJS Law, Rosen Law Firm, Hagens Berman, Faruqi & Faruqi and other firms highlights an August 17, 2026 deadline for investors to seek lead-plaintiff status. The repeated announcements increase the visibility of the legal issue and could raise concerns about potential financial, management and reputational costs for Embecta. Kaplan Fox Alerts Investors of a Securities Class Action Against Embecta
• Neutral Sentiment: The announcements primarily seek potential plaintiffs and do not represent a new court ruling, settlement or regulatory finding. Embecta’s previously reported quarterly results showed adjusted earnings and revenue above consensus, but revenue declined 8.1% year over year; the company’s FY 2026 earnings guidance remains $1.80–$1.90 per share.

Hedge Funds Weigh In On Embecta

Several hedge funds and other institutional investors have recently modified their holdings of EMBC. Royal Bank of Canada grew its holdings in shares of Embecta by 38.3% during the 1st quarter. Royal Bank of Canada now owns 18,201 shares of the company’s stock worth $232,000 after purchasing an additional 5,036 shares during the period. AQR Capital Management LLC raised its holdings in Embecta by 3.7% in the first quarter. AQR Capital Management LLC now owns 225,641 shares of the company’s stock valued at $2,738,000 after buying an additional 8,109 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in Embecta by 2.4% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,323 shares of the company’s stock valued at $629,000 after buying an additional 1,159 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in Embecta by 4.8% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 172,173 shares of the company’s stock valued at $2,195,000 after buying an additional 7,894 shares in the last quarter. Finally, Jane Street Group LLC lifted its position in Embecta by 224.0% during the first quarter. Jane Street Group LLC now owns 132,688 shares of the company’s stock valued at $1,692,000 after buying an additional 91,729 shares in the last quarter. 93.83% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

EMBC has been the subject of a number of analyst reports. Wall Street Zen cut Embecta from a “strong-buy” rating to a “hold” rating in a report on Saturday, May 9th. Weiss Ratings cut shares of Embecta from a “sell (d+)” rating to a “sell (d)” rating in a research note on Monday, August 3rd. BTIG Research lowered shares of Embecta from a “buy” rating to a “neutral” rating in a research report on Tuesday, May 5th. Zacks Research raised shares of Embecta from a “strong sell” rating to a “hold” rating in a research note on Friday, July 17th. Finally, Mizuho cut their price target on Embecta from $12.00 to $5.00 and set a “neutral” rating for the company in a report on Wednesday, May 6th. Three analysts have rated the stock with a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Reduce” and a consensus price target of $11.00.

Embecta Company Profile

Embecta Corp (NASDAQ: EMBC) is a pure-play diabetes care company that was spun off from Becton, Dickinson and Company on July 1, 2021. Headquartered in Franklin Lakes, New Jersey, Embecta focuses exclusively on the development, manufacturing and commercialization of products that enable insulin delivery and blood glucose monitoring for people with diabetes.

The company’s product portfolio includes insulin infusion sets, durable and patch pumps, pen needles, infusion tubing, blood glucose test strips, lancets and lancing devices.